Tsis ntev los no thawj zaug muab rau pej xeem Arcellx (ACLX) forged $325 lab ntau yam myeloma deal nrog Gilead Sciences (GILD) Hnub Friday, thiab IPO Tshuag tau tawg.
X
Cov xov xwm tuaj nyob rau hauv lockstep nrog kev cog lus ntev mus rau Arcellx txoj kev kho mob myeloma ntau. Txhua tus neeg mob uas muaj tsawg kawg ib hlis ntawm kev soj ntsuam tau teb rau Arcellx cov tshuaj. Yuav luag peb-plaub ntawm lawv, 71%, tau txais cov lus teb tiav, txhais tau tias lawv tsis pom cov tsos mob ntawm tus mob qog noj ntshav.
Tam sim no, Gilead yuav them Arcellx $ 225 lab rau pem hauv ntej thiab ua $ 100 lab kev nqis peev hauv IPO Tshuag. Nyob rau hauv rov qab Gilead's Kite division yuav codevelop thiab koom ua lag luam rau ntau yam myeloma tshuaj. Arcellx kuj tseem yuav tsim nyog tau txais kev them nyiaj tseem ceeb thiab qee cov nuj nqis. Gilead tau txais tus kws kho mob tshwj xeeb Kite Pharma hauv 2017.
Thaum sawv ntxov trading ntawm tus Tshuag lag luam hnub no, IPO Tshuag Arcellx rocketed 29.2% kaw ntawm 28.02. Qhov ntawd thawb shares saum toj no a muas point ntawm 27.01 tawm ntawm kev sib sau ua ke, raws li MarketSmith.com. Kile-a nyob ze ntawm 88.
IPO Tshuag: 100% Teb tus nqi
Cov txiaj ntsig ntev, kuj tau tshaj tawm rau hnub Friday, tau cog lus rau kev kho mob myeloma ntau.
Arcellx tau soj ntsuam 38 tus neeg mob uas tau txais kev kho mob tsawg kawg ib hlis dhau los. Cov neeg mob txhua tus tau pom qhov tsis zoo thiab tau mob zuj zus thaum tau txais tsawg kawg peb qhov kev kho mob ua ntej. Txhua tus neeg mob tau teb rau qhov kev sim tshuaj, nrog 71% qhia tsis pom cov tsos mob ntawm tus mob qog noj ntshav.
Ntawm cov neeg tau txais kev kho mob 12-18 lub hlis dhau los, 100% teb rau kev kho mob. Hauv pab pawg kho mob ib xyoos dhau los, 80% tsis muaj cov cim qhia tias mob qog noj ntshav thaum lawv kuaj lub Kaum Ib Hlis. Rau cov neeg uas tau txais kev kho mob Arcellx 18 lub hlis dhau los, 81% tau teb tag nrho.
Bullishly rau IPO Tshuag, tsis muaj cov teeb meem loj ntawm cytokine tso tawm syndrome, lossis CRS. CRS yog ib qho kev mob tshwm sim ntawm kev kho ntawm tes zoo li Arcellx's uas lub cev tsis muaj zog tiv thaiv cov tshuaj, ua rau muaj teeb meem hauv lub cev.
50-50 Cov Nyiaj Tshaj Tawm Hauv Tebchaws Meskas
Tam sim no, Arcellx yuav ua ntej nrog Gilead's Kite rau codevelop thiab koom ua lag luam cov tshuaj.
Ntxiv rau cov nyiaj ntsuab thiab kev ncaj ncees ua ntej, Arcellx tseem yuav tsim nyog tau txais txog $ 3.9 nphom hauv kev them nyiaj tseem ceeb. Lub tuam txhab yuav tau txais ib nrab nqi ntawm kev muag khoom sab nraum US Arcellx thiab Gilead yuav faib US cov txiaj ntsig 50-50.
Cov xov xwm hnub Friday xa Arcellx Tshuag mus rau nws qhov siab tshaj plaws-puas tau taw qhia.
Txawm hais tias Arcellx tsuas yog cuaj lub hlis tawm ntawm nws qhov kev tshaj tawm thawj zaug rau pej xeem, shares muaj zog Ntsuam Xyuas Lub Zog Muaj Zog ua 92, IB Digital. Qhov no tso IPO Tshuag hauv thawj 8% ntawm tag nrho cov khoom lag luam nyob rau hauv cov nqe lus ntawm 12-lub hlis kev ua tau zoo.
Ua raws li Allison Gatlin ntawm Twitter ntawm @IBD_AGatlin.
KOJ UA LI CAS:
Vim li cas Mirati Therapeutics Tshuag poob ib nrab ntawm nws tus nqi hauv peb hnub xwb
Cov Kev Xaiv Ua Lag Luam: Yuav Pib Siv Cov Kev Xaiv, Yuav Ua Li Cas Tswj Cov Kev Nyab Xeeb
Pom Qhov Kev Lag Luam Zoo Tshaj Plaws Sij Hawm Zoo Nrog IBD Cov Thawj Coj Ua Haujlwm Ntev
Tau Txais Cov Tswv Yim Npaj Los Ntawm IBD Kws Tshaj Lij Txhua Hmo Ua Ntej Qhib
Tau qhov twg los: https://www.investors.com/news/technology/ipo-stock-arcellx-breaks-out-on-cancer-deal-with-gilead/?src=A00220&yptr=yahoo